The Federal Trade Commission (FTC) is reportedly launching an investigation into recent shortages of chemotherapies, including carboplatin, cisplatin, and other drugs, aiming to understand the market dynamics contributing to the scarcity of crucial medicines in U.S. hospitals.
The FTC seeks insights into the practices of drug distributors and hospital purchasing groups, including contracting methodologies, market concentration, and compensation structures.
The agency is interested in exploring whether intermediaries facilitating drug purchases for hospitals and those involved in shipping medicines have potentially wielded their market influence to drive down the prices of ...